- Home
- RUM vs PTGX Comparison
RUM vs PTGX Comparison
Compare RUM & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RUM | PTGX |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | 156 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 6.4B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | RUM | PTGX |
|---|---|---|
| Price | $9.15 | $99.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $108.23 |
| AVG Volume (30 Days) | ★ 3.2M | 429.0K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | N/A |
| Revenue This Year | $209.98 | $874.25 |
| Revenue Next Year | $40.99 | N/A |
| P/E Ratio | ★ N/A | $1,996.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.62 | $47.53 |
| 52 Week High | $10.99 | $107.84 |
Technical Indicators
Market Signals| Indicator | RUM | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 64.19 | 47.90 |
| Support Level | $6.39 | $96.36 |
| Resistance Level | N/A | $100.00 |
| Average True Range (ATR) | 0.69 | 4.06 |
| MACD | 0.12 | -0.18 |
| Stochastic Oscillator | 79.21 | 33.37 |
Price Performance
Historical ComparisonAbout RUM Rumble Inc.
Rumble Inc is a free-to-use video-sharing and livestreaming platform where users can watch, share, like, comment, and upload their own videos. Users can follow channels to stay in touch with creators and access video on-demand (VOD) and live content streamed by creators. Geographically, it generates a majority of its revenue from the United States.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.